Aligos Therapeutics (ALGS) Cash from Operations (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Cash from Operations for 8 consecutive years, with -$25.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 60.93% year-over-year to -$25.0 million; the trailing twelve-month figure through Jun 2026 stood at -$94.2 million (down 25.7% YoY), and the FY2025 full-year result was -$82.5 million, down 2.18% from the prior year.
• Cash from Operations retreated to -$25.0 million in Q2 2026 per ALGS's latest filing, from -$23.1 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$13.6 million in Q2 2023 and bottomed at -$25.0 million in Q2 2022.
• Historically, Cash from Operations has averaged -$20.5 million across 5 years, with a median of -$20.7 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Cash from Operations soared 55.22% in 2022, then tumbled 60.93% in 2026.
• Over 5 years, Cash from Operations stood at -$16.8 million in 2022, then plunged by 35.01% to -$22.7 million in 2023, then gained by 18.78% to -$18.4 million in 2024, then fell by 18.16% to -$21.7 million in 2025, then retreated by 14.74% to -$25.0 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$25.0 million, -$23.1 million, and -$21.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.